Dianalitics
Tandem Diabetes Care, Inc.
TNDM · v1 · 2026-08-02
arrow_back
homeHomemonitoringPerformancesearch
hourglass
Loading…
Preparing the latest DD data, styles and content.
66OpportunityDD: Aug 02, 2026Analyst: 61
paidPrice at analysis date
USD 19.5 (02/08/2026)
domainMkt cap
-
pie_chartShares
-
candlestick_chart52W
2026-08
trending_downShort interest
16.0%
INFONASDAQHealth Care2500 employeesFounded 2006
Verdict: Favorable Risk/Reward — Binary earnings catalyst, real product moat

TNDM is a genuine dislocation: −74% from the 2021 peak of ~$75, currently at $19.50 vs a 52-week low of $9.98 and consensus PT of $28.53 (+46%). The company crossed $1B revenue in 2025, gross margin re-inflected to 55% in Q1 2026 (+5pts YoY), FCF turned positive, and Mobi Tubeless launch is imminent. Floor is not a hard cash floor (net debt ≈ neutral once you count the $602M 0% convertible), but the pump business at 1.0x EV/Sales — the strategic-buyer trough multiple — implies ~$14/share, giving a workable asymmetric setup. Q2 earnings on Aug 6 is the immediate binary; a beat and a guide-raise re-rates the multiple, a miss retests $12–14.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-08-02
61
Tandem Diabetes Care, Inc. (TNDM)
Medical Devices · NASDAQ · San Diego
"Real product, real revenue, real inflection; convertible refi risk far, catalyst near."
$1B+ revenue −74% from peak Q2 earnings 08-06 SI ~16% GM 55% (+5pt)
Fin. strength
13
/20 pts
EBITDA/FCF
8
/15 pts
Debt/leverage
9
/15 pts
Stage/business
12
/15 pts
Catalysts
8
/10 pts
Reg. risk
6
/8 pts
Risk/reward
5
/7 pts
Management
3
/5 pts
Sector/macro
2
/3 pts
Compliance
1
/2 pts
💡 Fair Value Estimate — EV/Sales peer-derived + net cash/convert bridge
Fair value base case
USD 26.0
Range: USD 13.0-USD 40.0
Price at analysis date: USD 19.5 (02/08/2026)
Base upside/downside: +33%

Method: EV/Sales peer-derived (primary) + DCF cross-check (+4%). Implicit EV/EBITDA 36x. Sensitivity ±0.3x EV/S → ±$4.7/sh — flagged as primary risk. Multiple within peer range (0.7x–6.2x); position at 1.7x justified by growth gap vs PODD/DXCM and pending class action. No reverse-engineering: FV built bottom-up from peer median → adjustments → multiple → EV → equity bridge.

ComponentAssumptionUSD/share
Core AID pump business EV$1.075B FY26E rev × 1.7x EV/Sales / 68.5M sh+26.68
Mobi Tubeless launch option30% prob × $180M NPV (share re-take vs Omnipod) / 68.5M+0.79
Pharmacy channel margin lift25% prob × $150M NPV (GM +200bps × 3yr NPV) / 68.5M+0.55
Cash + ST investments$570.3M (Q1 2026) / 68.5M sh+8.33
Convertible senior notes (0% due 2032)−$601.8M face / 68.5M sh — treated as debt at face (conv strike well above spot)−8.79
Class action reserve−$30M expected loss (Aug 2024–Aug 2025 class period) / 68.5M−0.44
SBC dilution reserve~2.5%/yr dilution × equity × 3y NPV / 68.5M−1.12
FV base caseSum of components above (rounded)≈ $26.00
Bull
$36–40
Probability: 25%
Q2 beat + guide-raise. Mobi Tubeless launches and takes share from Omnipod at pace. Pharmacy channel drives GM +300bps. EV/Sales re-rates to 2.8x. Peer gap narrows.
Base
$26
Probability: 45%
Guidance reiterated at $1.065–1.085B, 6% growth. GM stays ~55%. Modest FCF positive. Multiple re-rates to 1.7x from 1.3x current. Analyst PT $28.53 held.
Bear
$12–14
Probability: 30%
Q2 miss, guidance cut. Mobi Tubeless slips into 2027. Class action settles at $50–100M. GLP-1 permanently caps T1D pump TAM. Multiple compresses to 1.0x. Retests 52W low $9.98.
Methodology: Method: EV/Sales peer-derived (primary) + DCF cross-check (+4%). Implicit EV/EBITDA 36x. Sensitivity ±0.3x EV/S → ±$4.7/sh — flagged as primary risk. Multiple within peer range (0.7x–6.2x); position at 1.7x justified by growth gap vs PODD/DXCM and pending class action. No reverse-engineering: FV built bottom-up from peer median → adjustments → multiple → EV → equity bridge. Not investment advice.
⚠️ Methodology note: ASYMMETRY selection candidate. Sub-type: FALLEN_ANGEL + INFLECTION. Screening downside (floor ≈ $14, 1.0x EV/Sales strategic-buyer trough) = 28%; screening upside to consensus $28.53 = +46% (base) or +85% to a $36 re-rating scenario; screening ratio = 2.5–3.0x, passing the gate. The selection tag is a screening criterion — this DD derives fair value independently from peer multiples and DCF, and can legitimately conclude that the asymmetry is smaller than the screen implied.
📊 Capital Structure · Short Interest · Buyback & Dilution
🟡 Short Interest
~16.0%
~10.9M shares short (Nasdaq mid-Jul 2026), −7.9% MoM. Days-to-cover ~5. Elevated but not extreme; positioned for an earnings surprise either direction.
🔵 Share dilution (YoY)
+3.0%
Shares out 68.53M (Jul 2026) vs ~66.5M yr-ago = +3% dilution mainly from RSU vesting. No secondary follow-on. Feb 2026 convertible ($265M) is 0% coupon, non-dilutive until strike.
⚪ Buyback
$0
No active buyback authorization. Cash preserved for R&D, pharmacy channel build-out, potential class action settlement. Convertible refi window opens 2029–2032.
TNDM — 16.0% of float
16.0%
Peer average (PODD, DXCM, EMBC)
~5.5%

Insider transactions (Form 4 last 12 months): COO Jean-Claude Kyrillos bought shares in Mar 2025 (positive signal, aligned with the low). Directors Blickenstaff and Allen made modest sales during the 2024–2025 class period. No CEO or CFO sales identified. Total insider net activity ≈ neutral; the pattern reads as routine RSU vesting rather than conviction selling.

💰
Financial Analysis
FY25 revenue
$1.015B
+7.9% YoY
FY26 guidance
$1.07–1.09B
+5–7% YoY
Q1'26 gross margin
55.0%
+~5 pts YoY
Cash + ST inv.
$570M
Net convert debt −$31M
FY (USD M)FY23FY24FY25FY26E
Revenue$770$940$1,015$1,075
YoY growth−11%+22%+8%+6%
Gross margin48%50%51%55–56%
GAAP net income−$225−$96−$205−$60 to −$80
Adj. EBITDAn/m~$15~$40~$50–60
Free cash flow−$110−$45~$0Positive
Cash + ST inv.$390$290$570$500–550
Convert debt$337$337$602$602
Quarterly trend — sales, margin, cash (last 5 Qs)
MetricQ1'25Q2'25Q3'25Q4'25Q1'26
Revenue ($M)234.4241249290.4247.2
YoY growth+18%+9%+11%+3%+5%
Gross margin~50%~51%~52%~53%55%
GAAP net income ($M)−131−45−15−14−20
US pump shipments (k)~15~1720+27+~17
Cash + ST inv. ($M)293310340295570
Revenue growth (FY26E)
+6%
Gross margin (Q1'26)
55%
FCF conversion (FY26E)
~5%
Convertible refi runway
2032 due
account_tree

Business & Segments

Product portfolio & competitive position
TNDM is one of three US insulin-pump makers (alongside Insulet and Medtronic MiniMed) and the only pure-play AID (automated insulin delivery) small-cap. Flagship t:slim X2 pump + Control-IQ+ algorithm (FDA-cleared for T1D and now for pregnancy since Apr 2026); Tandem Mobi (world's smallest AID pump, 2024 launch); Mobi Tubeless (imminent H2 2026 launch — the strategic response to Omnipod dominance in tubeless). Direct international sales transition ongoing; PayGo pharmacy channel expanding US access.

t:slim X2 + Control-IQ+ (tubed AID) ~$660M FY26E (~61% rev) 🟡 mature Installed base of ~300k patients. FDA-cleared for T1D + pregnancy. Slow-growth core; defends installed base against Omnipod attrition. GM ~55%. Tandem Mobi (miniature AID) ~$220M FY26E (~20% rev) 🟢 ramping World's smallest AID pump, launched 2024. Android compatibility Mar 2026. Mobi Tubeless imminent H2 2026 — direct Omnipod 5 competitor. Key growth driver. International + PayGo channels ~$195M FY26E (~18% rev) 🟢 transitioning Direct international sales replacing distributors. Pharmacy PayGo model in US reduces OOP and expands access. GM tailwind expected 2027+. CE Mark T2D + pregnancy Jun 2026.

gavel

Risk Grid

Omnipod share loss
HIGH
Insulet's Omnipod 5 is the tubeless AID standard; TNDM must credibly re-take share with Mobi Tubeless. If launch slips or adoption weak, growth stays capped at 5–6% and multiple stays depressed.
Class action Aug 2024–2025
MEDIUM
Securities class action over Aug 2025 t:slim X2 speaker recall (−19.9% single-day drop). Multiple firms filing (Rosen, Bernstein Liebhard, Levi & Korsinsky). Estimated settlement range $30–100M — non-existential but material.
GLP-1 TAM compression
MEDIUM
GLP-1 adoption in T2D reduces pump-eligible population long-term. T1D TAM (core TNDM market) unaffected structurally, but T2D expansion strategy (via CE Mark) is more contested. 5-yr TAM narrative under pressure.
Convertible refi risk (2032)
LOW
$602M convertible senior notes due 2032, 0% coupon. Long runway; strike well above spot so no immediate dilution. Refi risk is 2029–2031 window if stock stays depressed and rates high.
Q2 earnings binary (Aug 6)
HIGH
Consensus $253M rev, GM ~55%, adj EBITDA breakeven+. Miss on guidance = retest $12–14. Beat + Mobi Tubeless timing update = re-rating trigger. Binary event 4 trading days away.
Real product moat
POSITIVE
Control-IQ+ is the most clinically-validated AID algorithm outside Medtronic. Multiple CGM integrations (Dexcom G7, Libre 3+). Sticky installed base; FDA-cleared pregnancy indication is a unique differentiator.
Gross margin inflection
POSITIVE
GM 48% (FY23) → 55% (Q1'26). Pharmacy channel + Mobi mix + operational leverage all contribute. If Q2 sustains 55%+, thesis validated; positive FCF confirmed.
Cash cushion + FCF turn
POSITIVE
$570M cash + ST inv (Q1'26) vs $602M convert due 2032 = essentially neutral net debt. FCF positive Q1'26 (+$5M). Runway multi-year even in bear case; no going-concern risk.
public

SWOT

Strengths
  • +Control-IQ+ clinically-validated AID algorithm with pregnancy indication (unique)
  • +$1B+ revenue base with GM inflection (48% → 55% in ~2 years)
  • +$570M cash + 0% convert = strong liquidity, no near-term refi
  • +Mobi is the smallest AID pump on market — real product differentiation
Weaknesses
  • −Growth decelerated to 5–7% vs peers PODD +21%, DXCM +11%
  • −Losing tubeless share to Omnipod 5 for 2+ years
  • −Convert debt $602M offsets nearly all cash — net debt neutral, no true "cash floor"
  • −Class action pending; management credibility dented by Aug 2025 recall
Opportunities
  • →Mobi Tubeless launch H2 2026 = direct Omnipod counter
  • →Pharmacy PayGo channel expands US access + lifts GM 200–300 bps
  • →T2D expansion via Control-IQ+ CE Mark (Jun 2026) opens 5x TAM
  • →Peer-multiple re-rating: 1.7x → 2.5–3.0x = $34–40 stock
Threats
  • !Insulet Omnipod 5 continues taking share; Sigi (Embecta) enters T2D
  • !GLP-1 permanently caps insulin-pump TAM growth
  • !Class action settlement cost creep + potential restatement risk
  • !Medtronic 780G integration with Simplera CGM could compress mid-tier
Bull case (25%)
Q2 beat + guide-raise on Aug 6
Mobi Tubeless taking share by Q4'26
Pharmacy channel drives GM +300bps
Multiple re-rates 1.7x → 2.8x → $36–40
Base case (45%)
Q2 in-line, guidance reiterated
GM stays ~55%, FCF slightly positive
Multiple drifts 1.3x → 1.7x → $26
Analyst PT $28.53 anchor holds
Bear case (30%)
Q2 miss, guidance cut to $1.05B
Mobi Tubeless slips into 2027
Class action settles $80M+
Multiple compresses to 1.0x → $12–14 (52W-low retest)
Sources & Disclaimer

Data sources: Tandem Diabetes Care Q1 2026 earnings release / 10-Q (SEC EDGAR); StockAnalysis.com (price, market cap, statistics, analyst PT, Fri 2026-07-31 close); Yahoo Finance; Business Wire press releases (CE Mark, FDA clearances, Mobi Tubeless, convertible pricing); Nasdaq short interest data; Rosen Law / Bernstein Liebhard / Levi & Korsinsky class action filings; peer data (PODD, DXCM, MDT, EMBC) from Yahoo Finance and Simply Wall St. Market data — last verified close 2026-07-31 ($19.50, +2.58%, previous close $19.01) — cross-checked between StockAnalysis.com and Yahoo Finance. ⚠️ Not investment advice. Report generated as part of an automated small-cap ASIMMETRIA screening run for research purposes. All catalyst dates are estimates unless official.